IgA nephropathy
Conditions
Interventions
three:Recombi-nant Human Interleu-kin-2 (125Ala) for Injecition
Sponsors
Shijiazhuang Kidney Disease Hospital Limited Liability Company
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-65 years old male and female; 2. 24 hours urinary protein quantitative continued in the 1.0 ~ 3.0g/d, and duration =3 months, eGFR =40ml/min.; 3. 3 years by the top three hospital renal biopsy diagnosis of IgA nephropathy; 4. despite the use of ACEI or ARB drugs and corticosteroids (=1.0mg/kg/d prednisone or equivalent) or immunosuppressive agents.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women; 2. Allergy to the drug used; 3. Consolidation of the nervous system, mental illness 4. combined with severe lung, heart, liver dysfunction; 5. combined with digestive tract ulcers, bleeding and other diseases of the digestive system patients; 6. severe diabetes, active or chronic infection, thromboembolism and other serious complications and malignant tumor patients; Hypertension patients with systolic blood pressure> 180mmHg or diastolic blood pressure> 110mmHg patients; 8. Henoch-Schonlein purpura nephritis, systemic lupus erythematosus, chronic alcoholic cirrhosis and other secondary IgA nephropathy; 9. Use of high-dose glucocorticoids (> 1.5mg/kg/d) in the last month, with a history of treatment with rituximab or other biologics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein quantity; | — |
Countries
China
Contacts
Public ContactLi Junwei
Shijiazhuang Kidney Disease Hospital Limited Liability Company
Outcome results
None listed